27823981|t|Repetitive transcranial magnetic stimulation improves cognitive function of Alzheimer's disease patients
27823981|a|Repetitive transcranial magnetic stimulation (rTMS) acts as a kind of widely-applied and non-invasive method in the intervention of some neurological disorders. This prospective, randomized, double-blind, placebo-controlled trial investigates the effect of rTMS on 30 cases of Alzheimer's disease (AD) participants, who were classified into mild and moderate groups. Neuropsychological tests were carried out using the AD Assessment Scale - cognitive subscale (ADAS - cog), Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), and World Health Organization University of California-Los Angeles, Auditory Verbal Learning Test (WHO-UCLA AVLT) before, immediately after, and 6 weeks after the intervention. In this work, data from 30 AD patients revealed that there was no obvious interaction effect of time-by-group. The ADAS - cog, MMSE and WHO-UCLA AVLT score in the rTMS group was significantly improved compared with baselines at 6 weeks after treatment (all p<0.05). Meanwhile, MoCA scores were also obviously ameliorated in the mild AD patients with rTMS. Besides, subgroup analysis showed that the effect of rTMS on the memory and language of mild AD patients was superior to those of moderate AD patients. In conclusion, our findings suggested that repetitive transcranial magnetic stimulation improves cognitive function, memory and language level of AD patients, especially in the mild stage of AD. Thus, rTMS can be recommended as a promising adjuvant therapy combined with cholinesterase inhibitors at the mild stage of AD patients.
27823981	0	44	Repetitive transcranial magnetic stimulation	T061	C0872259
27823981	54	72	cognitive function	T041	C0392335
27823981	76	95	Alzheimer's disease	T047	C0002395
27823981	96	104	patients	T101	C0030705
27823981	105	149	Repetitive transcranial magnetic stimulation	T061	C0872259
27823981	151	155	rTMS	T061	C0872259
27823981	221	233	intervention	T061	C0184661
27823981	242	264	neurological disorders	T047	C0027765
27823981	271	282	prospective	T062	C0033522
27823981	284	294	randomized	T062	C0034656
27823981	296	308	double-blind	T062	C0013072
27823981	310	334	placebo-controlled trial	T062	C1706408
27823981	335	347	investigates	T169	C1292732
27823981	362	366	rTMS	T061	C0872259
27823981	373	378	cases	T169	C0868928
27823981	382	401	Alzheimer's disease	T047	C0002395
27823981	403	405	AD	T047	C0002395
27823981	407	419	participants	T098	C0679646
27823981	446	450	mild	T080	C2945599
27823981	455	463	moderate	T080	C0205081
27823981	464	470	groups	T098	C1257890
27823981	472	496	Neuropsychological tests	T060	C0027902
27823981	524	543	AD Assessment Scale	T170	C0450989
27823981	546	564	cognitive subscale	T170	C0282574
27823981	566	570	ADAS	T170	C0450989
27823981	573	576	cog	T170	C0282574
27823981	579	608	Mini-Mental State Examination	T060	C0451306
27823981	610	614	MMSE	T060	C0451306
27823981	617	646	Montreal Cognitive Assessment	T170	C3496286
27823981	648	652	MoCA	T170	C3496286
27823981	659	752	World Health Organization University of California-Los Angeles, Auditory Verbal Learning Test	T170	C0589055
27823981	754	767	WHO-UCLA AVLT	T170	C0589055
27823981	802	807	weeks	T079	C0439230
27823981	818	830	intervention	T061	C0184661
27823981	846	850	data	T078	C1511726
27823981	859	861	AD	T047	C0002395
27823981	862	870	patients	T101	C0030705
27823981	906	924	interaction effect	UnknownType	C0548930
27823981	947	951	ADAS	T170	C0450989
27823981	954	957	cog	T170	C0282574
27823981	959	963	MMSE	T060	C0451306
27823981	968	981	WHO-UCLA AVLT	T170	C0589055
27823981	982	987	score	T081	C0449820
27823981	995	999	rTMS	T061	C0872259
27823981	1000	1005	group	T098	C1257890
27823981	1033	1041	compared	T052	C1707455
27823981	1047	1056	baselines	T081	C1442488
27823981	1062	1067	weeks	T079	C0439230
27823981	1074	1083	treatment	T061	C0087111
27823981	1109	1113	MoCA	T170	C3496286
27823981	1114	1120	scores	T081	C0449820
27823981	1141	1152	ameliorated	T033	C0184511
27823981	1160	1164	mild	T080	C2945599
27823981	1165	1167	AD	T047	C0002395
27823981	1168	1176	patients	T101	C0030705
27823981	1182	1186	rTMS	T061	C0872259
27823981	1197	1214	subgroup analysis	T062	C0936012
27823981	1241	1245	rTMS	T061	C0872259
27823981	1253	1259	memory	T041	C0025260
27823981	1264	1272	language	T171	C0023008
27823981	1276	1280	mild	T080	C2945599
27823981	1281	1283	AD	T047	C0002395
27823981	1284	1292	patients	T101	C0030705
27823981	1318	1326	moderate	T080	C0205081
27823981	1327	1329	AD	T047	C0002395
27823981	1330	1338	patients	T101	C0030705
27823981	1359	1367	findings	T033	C0243095
27823981	1383	1427	repetitive transcranial magnetic stimulation	T061	C0872259
27823981	1437	1455	cognitive function	T041	C0392335
27823981	1457	1463	memory	T041	C0025260
27823981	1468	1476	language	T171	C0023008
27823981	1477	1482	level	T080	C0441889
27823981	1486	1488	AD	T047	C0002395
27823981	1489	1497	patients	T101	C0030705
27823981	1517	1521	mild	T080	C2945599
27823981	1522	1527	stage	T079	C0205390
27823981	1531	1533	AD	T047	C0002395
27823981	1541	1545	rTMS	T061	C0872259
27823981	1580	1596	adjuvant therapy	T061	C0677850
27823981	1611	1636	cholinesterase inhibitors	T109,T121	C0008425
27823981	1644	1648	mild	T080	C2945599
27823981	1649	1654	stage	T079	C0205390
27823981	1658	1660	AD	T047	C0002395
27823981	1661	1669	patients	T101	C0030705